Cellectis (NASDAQ: CLLS) reported Q2 EPS of (EUR0.36), EUR0.05 worse than the analyst estimate of (EUR0.31). Revenue for the quarter came in at EUR1 million versus the consensus estimate of EUR5.6 million.

As of September 30, 2015 Cellectis had €279.4 million in cash and cash equivalents compared to €112.3 million as of December 31, 2014. This increase is primarily attributable to the $228 million of proceeds from Cellectis’ U.S. initial public offering in March 2015, partly offset by €22 million of cash flows used in operating activity, €3.3 million of acquisitions of tangible assets, and the repurchase for €3.5 million of 25% of the minority shares of Cellectis Bioresearch S.A.S, in each case during the first nine months of 2015.

For earnings history and earnings-related data on Cellectis (CLLS) click here.